Table 1.
Correlations between colonic restriction factor gene transcripts and clinical, virological and immunological parameters.a
| Tetherin (N=16) |
APOBEC3G (N=16) |
MX2 (N=17)b |
|
|---|---|---|---|
| Clinical Parameters | |||
| Blood CD4 T cell count | R=−0.31, P=0.24 | R=−0.19, P=0.47 | R=−0.14, P=0.58 |
| Plasma HIV-1 viral load | R=0.51, P<0.05 | R=0.36, P=0.18 | R=0.46, P=0.07 |
| Systemic inflammation, immune activation, microbial translocation and epithelial barrier disruption parameters | |||
| Plasma IL-6 | R=0.33, P=0.22 | R=0.32, P=0.22 | R=0.00, P=0.98 |
| Plasma CRP | R=0.00, P=1.0 | R=0.23, P=0.39 | R=−0.12, P=0.66 |
| Plasma TNFα (N=13c, 14d ) | R=0.60, P=0.03 | R=0.51, P=0.08 | R=0.33, P=0.30 |
| Plasma IFNγ (N=13, 12) | R=0.45, P=0.12 | R=0.18, P=0.55 | R=0.57, P=0.06 |
| Plasma IL-10 (N=13, 12) | R=0.84, P=0.0007 | R=0.79, P=0.002 | R=0.47, P=0.13 |
| Activated blood CD4 T cells | R=0.30, P=0.26 | R=0.29, P=0.27 | R=0.07, P=0.77 |
| Activated blood CD8 T cells | R=0.48, P=0.06 | R=0.46, P=0.08 | R=0.05, P=0.85 |
| Plasma sCD27 | R=0.32, P=0.23 | R=0.31, P=0.25 | R=0.24, P=0.36 |
| Plasma sCD14 (N=14, 14) | R=0.71, P=0.006 | R=0.39, P=0.17 | R=0.32, P=0.26 |
| Plasma LPS (N=15, 15) | R=0.43, P=0.11 | R=0.29, P=0.29 | R=0.27, P=0.33 |
| Plasma LTA (N=14, 14) | R=0.10, P=0.74 | R=−0.21, P=0.47 | R=0.13, P=0.66 |
| Plasma iFABP | R=−0.56, P=0.03 | R=−0.45, P=0.08 | R=−0.31, P=0.23 |
| Colonic immunity parameters | |||
| HIV-1 RNA levels | R=0.60, P=0.02 | R=0.54, P=0.03 | R=0.53, P=0.03 |
| No. of CD1c+ mDC (N=14, 16) |
R=−0.38, P=0.19 | R=−0.28, P=0.33 | R=−0.47, P=0.07 |
| No. of pDC (N=14, 16) | R=0.38, P=0.16 | R=0.44, P=0.10 | R=0.18, P=0.51 |
| CD1c+ mDC: CD40e (N=14, 16) | R=0.68, P=0.009 | R=0.83, P=0.0005 | R=0.46, P=0.07 |
| pDC CD40 (N=14, 15) | R=−0.06, P=0.84 | R=0.17, P=0.56 | R=−0.15, P=0.59 |
| CD1c+ mDC: CD83f
(N=14, 16) |
R=0.14, P=0.64 | R=0.24, P=0.40 | R=0.14, P=0.61 |
| pDC: CD83 (n=15, 16) | R=0.17, P=0.55 | R=0.22, P=0.41 | R=−0.17, P=0.53 |
| No. of CD4 T cellsg | R=0.03, P=0.92 | R=0.20, P=0.45 | R=0.05, P=0.86 |
| No. of CD8 T cells | R=0.22, P=0.41 | R=0.02, P=0.93 | R=0.10, P=0.72 |
| No. of activated CD4 T cells | R=0.29, P=0.28 | R=0.21, P=0.44 | R=0.27, P=0.31 |
| No. of activated CD8 T cells | R=0.52, P=0.04 | R=0.42, P=0.11 | R=0.42, P=0.09 |
| No. of IFNγ+ CD4 T cells (N=15, 16) |
R=0.05, P=0.87 | R=−0.05, P=0.86 | R=0.05, P=0.87 |
| No. of IL-17+ CD4 T cells (N=15, 16) |
R=0.17, P=0.55 | R=0.10, P=0.73 | R=0.24, P=0.37 |
| No. of IL-22+ CD4 T cells (N=15, 16) |
R=−0.02, P=0.94 | R=0.07, P=0.81 | R=0.09, P=0.74 |
| No. of IFNγ+ CD8 T cells (N=15, 16) |
R=−0.26, P=0.34 | R=−0.13, P=0.64 | R=−0.26, P=0.33 |
| IL-12p70h (N=13, 13) | R=0.64, P=0.02 | R=0.65, P=0.02 | R=0.35, P=0.24 |
| IL-23 (N=13, 13) | R=0.42, P=0.16 | R=0.46, P=0.12 | R=0.18, P=0.57 |
| IL-10 (N=13, 13) | R=0.44, P=0.14 | R=0.45, P=0.13 | R=0.19, P=0.54 |
| IL-1β (N=13, 13) | R=0.37, P=0.22 | R=0.35, P=0.24 | R=0.15, P=0.62 |
| TNFα (N=13, 13) | R=0.29, P=0.33 | R=0.30, P=0.32 | R=0.08, P=0.80 |
| IL-6 (N=13, 13) | R=0.40, P=0.18 | R=0.35, P=0.24 | R=0.25, P=0.42 |
| IFNγ (N=13, 13) | R=0.31, P=0.30 | R=0.32, P=0.28 | R=0.04, P=0.89 |
| IL-17 (N=13, 13) | R=0.29, P=0.34 | R=0.25, P=0.41 | R=0.10, P=0.74 |
Statistical analysis performed using the Spearman test.
a
Bold font indicates statistically significant correlation.
b
Outlier identified using Rout test was not included in analyses.
c
N denotes when not all study participants with tetherin/APOBEC3G or MX2
d
measurements had immunological data.
e
CD40 expression levels.
f
Percent of CD83.
g
No.: number per gram.
h
Constitutive production.